ST. LOUIS--(BUSINESS WIRE)-- #CMS--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved coverage for FDA-approved ColoSense, a stool-based colorectal (CRC) screening test, within the National Coverage Determination (NCD) for colorectal cancer screening tests. Coverage for ColoSense provides Medicare's approximately 65 million eligible be